A review of the cardiometabolic risk experience among Canadian Métis populations

Heather J A Foulds1, Mamdouh M Shubair, Darren E R Warburton

  • 1Experimental Medicine Program, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Insights

Métis populations in Canada face a higher burden of cardiometabolic risk, including diabetes and obesity. Addressing social and lifestyle factors is crucial for reducing these chronic conditions.

Area of Science:

  • Public Health
  • Epidemiology
  • Indigenous Health

Background:

  • Cardiometabolic risk factors like cardiovascular disease, diabetes, and obesity are increasing in Western societies.
  • Aboriginal populations disproportionately experience these chronic conditions, with limited data on Métis populations.
  • Métis communities face significant health disparities compared to non-Aboriginal Canadians.

Purpose of the Study:

  • To review and evaluate the cardiometabolic risk experience among Métis populations in Canada.
  • To understand the prevalence of cardiometabolic conditions within this specific Indigenous group.

Main Methods:

  • A comprehensive literature review was conducted.
  • Data on cardiometabolic risk, chronic conditions, and social determinants of health were synthesized.
  • Comparisons were made between Métis, First Nations, and non-Aboriginal populations.

Main Results:

  • Métis populations exhibit higher rates of metabolic syndrome, diabetes, obesity, and cardiovascular disease than non-Aboriginal Canadians.
  • Poorer life expectancy, lower educational and employment attainment, and reduced healthcare access are prevalent among Métis.
  • Health challenges and influencing factors for Métis are more aligned with First Nations than non-Aboriginal populations.

Conclusions:

  • Métis populations bear a greater burden of cardiometabolic risk and its components compared to the general Canadian population.
  • Interventions targeting sociodemographic, lifestyle, and social determinants are essential for mitigating chronic disease.
  • Métis must be included in broader strategies aimed at reducing chronic conditions among all Aboriginal peoples in Canada.

Related Concept Videos

Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...